• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Omnipaque sales top half-billion mark

Article

Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505

Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505 million and was ranked 37th on thepublication's list.

The majority of Omnipaque's revenue derived from U.S. sales,which were pegged at $480 million in 1993 -- up 1% from the $475million in sales recorded the year before.

The next best selling imaging agent on the list was Bristol-MyersSquibb's Isovue. The x-ray imaging product recorded worldwidesales of $310 million in 1993, down 7.4% from the $335 millionregistered in 1992. Isovue had U.S. sales of $305 million in 1993and $320 million the year before.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.